Insilico Medicine announced the first‑in‑patient dosing of MEN2501—a small‑molecule oncology candidate discovered using generative AI—under a licensing deal with Menarini, triggering a $5 million milestone payment. The Phase 1 dosing marks one of the earlier examples of an AI‑discovered drug reaching human trials and activating commercial milestones in a partnership. Insilico, which applies generative models and de novo design, framed the milestone as validation of AI-enabled discovery workflows and a commercial proof point for algorithm-driven pipelines. Menarini will continue clinical development under the license arrangement while Insilico remains eligible for upstream and downstream payments. The announcement is likely to accelerate investor and partner interest in AI-first discovery firms, while regulators and trialists will monitor whether AI‑originated chemical series translate to conventional pharmacology and safety expectations in clinic.